Vera Therapeutics Completes Enrollment For Primary Endpoint In Pivotal Phase 3 ORIGIN 3 Trial Of Atacicept In IgAN

Benzinga · Sep 12 20:01

On track to announce topline results from ORIGIN 3 trial in Q2 2025
Expect to present 96-week data from ORIGIN Phase 2b clinical trial of atacicept in IgAN in Q4 2024

BRISBANE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed enrollment ahead of schedule for the primary endpoint in the pivotal Phase 3 ORIGIN 3 trial of atacicept in patients with IgAN. The enrollment of 200 participants in this initial cohort of the trial will provide data for the 36-week UPCR primary efficacy endpoint, supporting the subsequent submission for regulatory approval.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Vera Therapeutics Completes Enrollment For Primary Endpoint In Pivotal Phase 3 ORIGIN 3 Trial Of Atacicept In IgAN

Risk Disclaimer